GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Institutional Ownership

Kyorin Pharmaceutical Co (TSE:4569) Institutional Ownership : 21.37% (As of Apr. 18, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kyorin Pharmaceutical Co's institutional ownership is 21.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kyorin Pharmaceutical Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kyorin Pharmaceutical Co's Float Percentage Of Total Shares Outstanding is 0.00%.


Kyorin Pharmaceutical Co Institutional Ownership Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Institutional Ownership Chart

Kyorin Pharmaceutical Co Historical Data

The historical data trend for Kyorin Pharmaceutical Co can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 20.29 19.50 19.52 18.89 19.97 20.32 21.15 21.29 21.27 21.37

Kyorin Pharmaceutical Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Kyorin Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co Headlines

No Headlines